---
title: "Penumbra reports THUNDER study results for THUNDERBOLT stroke device"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293508960.md"
description: "Penumbra reported results from the THUNDER IDE study for its THUNDERBOLT computer-assisted vacuum thrombectomy system in ELVO stroke. The study met performance goals, with 87.5% achieving successful reperfusion and a first-pass success rate of 64.8%. Median time to revascularization was 20 minutes, with serious adverse events at 2.8%. Penumbra confirmed the device has received US FDA clearance and a CE mark."
datetime: "2026-07-22T18:35:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293508960.md)
  - [en](https://longbridge.com/en/news/293508960.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293508960.md)
---

# Penumbra reports THUNDER study results for THUNDERBOLT stroke device

-   Penumbra released THUNDER IDE study results for its THUNDERBOLT computer-assisted vacuum thrombectomy system in ELVO stroke. \* Study met its performance goal, with 87.5% achieving successful reperfusion (mTICI 2b-3); first-pass success was 64.8%. \* Median time to revascularization was 20 minutes; serious device or procedure-related adverse events were 2.8%. \* Penumbra said THUNDERBOLT has received US FDA clearance and a CE mark. \* Full release: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607221435PR\_NEWS\_USPR\_\_\_\_\_SF10287) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PEN.US](https://longbridge.com/en/quote/PEN.US.md)

## Related News & Research

- [Penumbra posts press release on first patient enrolled in FORWARD distal stroke thrombectomy study](https://longbridge.com/en/news/291938143.md)
- [Boston Scientific FY26 Q2 net income rises 13.8% to 907 million; net sales climb 7.5% to 5.44 billion](https://longbridge.com/en/news/294679274.md)
- [FINQ’s AI-Managed ETFs Are On Fire: Returning 15.67% and 19.05% Since Launch](https://longbridge.com/en/news/294693492.md)
- [12:20 ETKLADNÉ STANOVISKO CHMP PODPORUJE ŠIRŠÍ POUŽITÍ PŘÍPRAVKU REPATHA® SPOLEČNOSTI AMGEN PŘED PRVNÍM INFARKTEM NEBO MOZKOVOU MRTVICÍ](https://longbridge.com/en/news/294537680.md)
- [How the 'Nostradamus of AI' failed to spot a market crash](https://longbridge.com/en/news/294580418.md)